CytoDyn (CYDY) Share-based Compensation (2010 - 2026)
CytoDyn (CYDY) posted Share-based Compensation of $444000.0 for Q1 2026, down 68.29% on a QoQ basis from $1.4 million in Q4 2025, and up 1010.0% year-over-year from $40000.0 in Q1 2025.
CytoDyn (CYDY) Share-based Compensation (2010 - 2026) Analysis & Trends
CytoDyn's Share-based Compensation history runs 17 years deep, the most recent figure standing at $444000.0 for Q1 2026.
- Quarterly Share-based Compensation rose 1010.0% year-over-year to $444000.0 in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $1.3 million (up 6.59% YoY) and the FY2025 annual result came in at $1.7 million, down 29.61% from the prior year.
- Share-based Compensation was $444000.0 for Q1 2026 at CytoDyn, down from $1.4 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $2.0 million in Q2 2022 and bottomed at -$400000.0 in Q1 2022.
- A 5-year average of $478470.6 and a median of $345000.0 in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation slumped 121.05% — and 2026, when it jumped 1010.0%.
- CytoDyn's Share-based Compensation stood at $310000.0 in 2022, then sank by 68.39% to $98000.0 in 2023, then jumped by 447.96% to $537000.0 in 2024, then soared by 160.71% to $1.4 million in 2025, then slumped by 68.29% to $444000.0 in 2026.
- Business Quant data shows CYDY's Share-based Compensation at $444000.0 in Q1 2026, $1.4 million in Q4 2025, and $179000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | CytoDyn | 267.79 Mn | 267.79 Mn | - | 444,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 444,000.00 |
| Feb 28, 2026 | 444,000.00 |
| Nov 30, 2025 | 1.40 Mn |
| Nov 30, 2025 | 1.40 Mn |
| Aug 31, 2025 | 179,000.00 |
| Aug 31, 2025 | 179,000.00 |
| May 31, 2025 | 599,000.00 |
| May 31, 2025 | 599,000.00 |
| Feb 28, 2025 | 40,000.00 |
| Feb 28, 2025 | 40,000.00 |
| Nov 30, 2024 | 537,000.00 |
| Nov 30, 2024 | 537,000.00 |
| Aug 31, 2024 | 136,000.00 |
| Aug 31, 2024 | 136,000.00 |
| May 31, 2024 | 471,000.00 |
| May 31, 2024 | 471,000.00 |
| Feb 29, 2024 | 900,000.00 |
| Feb 29, 2024 | 900,000.00 |
| Nov 30, 2023 | 98,000.00 |
| Nov 30, 2023 | 98,000.00 |